Trevi Therapeutics, Inc. is a clinical stage biotechnology company focused on developing Nalbuphine ER for chronic pruritus (itch).

Trevi Therapeutics Announces Initiation of a Pivotal Study of Nalbuphine ER in Uremic Pruritus
Study will enroll 360 patients in the United States and Europe
Trevi Therapeutics Announces $25 Million Series B Financing Led by TPG Biotech for Development of Nalbuphine ER
Company initiating activities for pivotal trials in chronic pruritic conditions of uremic pruritus and prurigo nodularis
Trevi Therapeutics Exhibits Poster at 2014 Annual Meeting of the Society for Investigative Dermatology
Proof-of-concept study with pharmacokinetics demonstrates anti-pruritic activity of oral nalbuphine ER in hemodialysis patients with uremic pruritus